NCT00905008Unknown不适用
Long-Term Safety and Efficacy of Drug Eluting Stents in "Real World" - Results From the FReIburger STent Registry
University Hospital Freiburg0 个研究点目标入组 1,502 人开始时间: 2006年10月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 1,502
- 主要终点
- All cause mortality (cardiac- and non-cardiac death).
研究概览
简要总结
The FReIburger STent Registry (FRIST) is designed to determine the long term safety and efficacy of Drug Eluting Stents (DES) in a "real-world" patient population requiring stent implantation.
FRIST included patients treated with DES and bare-metal stents (BMS) in the University Hospital of Freiburg, Germany, according to a non-restrictive inclusion criterion, in which virtually all consecutive patient subsets were considered eligible.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Consecutive patients undergoing percutaneous coronary intervention
排除标准
- •Patient refusal or inability to provide written informed consent
结局指标
主要结局
All cause mortality (cardiac- and non-cardiac death).
时间窗: 5 years
次要结局
- The composite of death and MI and stent thrombosis.(5 years)
- The occurrence of TVR, stroke, major bleeding, sepsis and tumor were also assessed.(5 years)
研究者
相似试验
招募中
不适用
Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical PracticePercutaneous Transluminal Coronary AngioplastyCoronary Artery DiseaseNCT01186133Seung-Jung Park50,000
招募中
2 期
Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)Primary Biliary CholangitisNCT06365424Xijing Hospital of Digestive Diseases117
招募中
不适用
Special Drug Use-results Survey for Long-term Use (Fostamatinib)Chronic Idiopathic Thrombocytopenic PurpuraNCT06757257Kissei Pharmaceutical Co., Ltd.149
已完成
不适用
An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).Cardiovascular DiseasesVascular DiseaseAtherosclerosisArteriosclerosisArterial Occlusive DiseaseNCT00489320Cordis Corporation7,759
进行中（未招募）
3 期
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXHemophiliaNCT03754790Genzyme, a Sanofi Company281